Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Paclitaxel/pertuzumab/trastuzumab

Systemic sclerosis‑interstitial lung disease: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ohara M, et al. Association between CA 15-3 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report. Molecular and Clinical Oncology 17: 145, No. 4, Oct 2022. Available from: URL: http://www.spandidos-publications.com/mco/ Ohara M, et al. Association between CA 15-3 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report. Molecular and Clinical Oncology 17: 145, No. 4, Oct 2022. Available from: URL: http://​www.​spandidos-publications.​com/​mco/​
Metadaten
Titel
Paclitaxel/pertuzumab/trastuzumab
Systemic sclerosis‑interstitial lung disease: case report
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25565-4

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Propranolol

Case report

Vancomycin